Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Sanjay S. Patel, CFA, as Chief Financial Officer, effective July 15, 2019. Mr. Patel replaces Tamara A. Seymour, who has served as the company’s Interim Chief Financial Officer since April 26, 2019.
Immunic appoints Sanjay S. Patel as CFO
AppointmentsImmunic, Inc., a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Sanjay S. Patel, CFA, as Chief Financial Officer, effective July 15, 2019. Mr. Patel replaces Tamara A. Seymour, who has served as the company’s Interim Chief Financial Officer since April 26, 2019.
Novo Holdings puts $72m in Lanzatech
Latest NewsGoogle maps for tumours and organs
Latest NewsTransgene’s licenced oncolytic virus fails in Phase III
Latest NewsSillaJen, the licensor for French immunoncology specialist Transgene SA, has stopped enrolment into the Phase III Phocus trial after an Independent Data Review Comittee predicted the study endpoint won’t be met.
Pieris Pharmaceuticals appoints Dr. Maya Said
AppointmentsPieris Pharmaceuticals, Inc. today announced that Maya R. Said, Sc.D., has joined the Company’s Board of Directors.
Wellington Partners launch €210m Life Sciences fund
Latest NewsWellington Partners has closed its largest Life Sciences Fund ever. The VC specialist outperformed its intial target of raising €120m to €150m and closed at €210m.
Alizé Pharma 3 bags largest EU financing so far
Latest NewsVenture Captital specialist LSP led a €67m Series A financing in peptide developer Alizé Pharma 3.
Better TNF? receptor blockers on the horizon
Latest NewsTwo research teams have unraveled the complex dynamics of TNF? receptor signaling and have identified compounds that may be safer than current treatments.
We need predictive safety biomarkers
OpinionEvery year, drug developers lose billions of euros because of late-stage clinical or postmarking safety problems with drugs. A recently kicked-off IMI consortium now wants to qualify a set of safety biomarkers that allow for the prediction of drug-induced injury of kidney, liver, vasculature, CNS, and pancreas. European Biotechnology spoke with Dr Michael Merz, the coordinator of the TransBioLine Project, and consortium member Prof Dr Stefan Wnendt about the plans and impact of the project.
AgroSavfe raises €35m in Series C financing
Latest NewsPlant protection specialist AgroSavfe will use the funds of a €35m Series C financing to push the development, registration and commercial scale production of its biofungicides and bio-insecticide.